Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is GuangYuYuan Chinese Herbal Medicine Co EV-to-EBIT?
GuangYuYuan Chinese Herbal Medicine CoSHSE:600771 58 EV-to-EBIT is 54.62 as of Sep. 15, 2026, which is 28% below its 10-year median of 75.36. GuruFocus rates SHSE:600771 with a GF Score™ of 58/100 and a GF Value™ of ¥22.09 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 684 Drug Manufacturers companies, GuangYuYuan Chinese Herbal Medicine Co ranks worse than 85.38% on this metric.
SHSE:600771'
s EV-to-EBIT Range Over the Past 10 Years
Min: -371.42 Med: 75.36 Max: 2244.56
Current: 54.62
During the past 13 years, the highest EV-to-EBIT of GuangYuYuan Chinese Herbal Medicine Co was 2244.56. The lowest was -371.42. And the median was 75.36.
SHSE:600771's EV-to-EBIT is ranked worse than 85.38% of 684
companies
in the Drug Manufacturers industry
Industry Median: 15.84
vs SHSE:600771: 54.62
GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
GuangYuYuan Chinese Herbal Medicine Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥5,870 Mil.
GuangYuYuan Chinese Herbal Medicine Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥112 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuangYuYuan Chinese Herbal Medicine Co EV-to-EBIT Related Terms
GuangYuYuan Chinese Herbal Medicine Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuangYuYuan Chinese Herbal Medicine Co EV-to-EBIT Chart
GuangYuYuan Chinese Herbal Medicine Co Annual Data
SHSE:600771 vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, GuangYuYuan Chinese Herbal Medicine Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GuangYuYuan Chinese Herbal Medicine Co EV-to-EBIT vs Drug Manufacturers Industry
GuangYuYuan Chinese Herbal Medicine Co's current Enterprise Value is ¥6,113 Mil.
GuangYuYuan Chinese Herbal Medicine Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥112 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) has a EV-to-EBIT of 54.62 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GuangYuYuan Chinese Herbal Medicine Co and its competitors. This is 28% below median its historical median of 75.36. According to the industry distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #584 out of 684 companies in the Drug Manufacturers industry, placing it in the top 85.4%.
Is GuangYuYuan Chinese Herbal Medicine Co's EV-to-EBIT too high?
GuangYuYuan Chinese Herbal Medicine Co's current EV-to-EBIT of 54.62 is 28% below median its 10-year median of 75.36. The Drug Manufacturers industry median EV-to-EBIT is 15.84. GuangYuYuan Chinese Herbal Medicine Co's value of 54.62 is 244.8% above this industry median. Based on the distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #584 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GuangYuYuan Chinese Herbal Medicine Co has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GuangYuYuan Chinese Herbal Medicine Co's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #584 out of 684 companies for EV-to-EBIT. This places GuangYuYuan Chinese Herbal Medicine Co in the lower half of its industry. The industry median EV-to-EBIT is 15.84. GuangYuYuan Chinese Herbal Medicine Co's value of 54.62 is 244.8% above this benchmark. While the company's 10-year median is 75.36 vs. the industry median of 15.84, GuangYuYuan Chinese Herbal Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GuangYuYuan Chinese Herbal Medicine Co's current EV-to-EBIT of 54.62 is 244.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on GuangYuYuan Chinese Herbal Medicine Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GuangYuYuan Chinese Herbal Medicine Co's current EV-to-EBIT is 54.62, which is 28% below median its own 10-year median of 75.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GuangYuYuan Chinese Herbal Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.09, compared to a current price of ¥13.43 — trading 39.2% below its estimated fair value. The current EV-to-EBIT is 54.62, which is 28% below median its 10-year median of 75.36 and 244.8% above the Drug Manufacturers industry median of 15.84. GuangYuYuan Chinese Herbal Medicine Co's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771), the current EV-to-EBIT is 54.62 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) Overvalued in 2026?
Based on GuruFocus' analysis, GuangYuYuan Chinese Herbal Medicine Co stock appears to be undervalued.
The current stock price of ¥13.43 is trading 39.2% below its estimated GF Value™ of ¥22.09.
GuruFocus considers GuangYuYuan Chinese Herbal Medicine Co to be Significantly Undervalued.
Key valuation signals for SHSE:600771:
EV-to-EBIT: 54.62 (28% below median its 10-year median of 75.36)
GF Value™: ¥22.09 vs. price of ¥13.43 (39.2% below fair value)
Industry Position: 244.8% above the Drug Manufacturers median (#584 of 684)
No single metric tells the full story. See the SHSE:600771 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.
58GF Score
Get the complete analysis for SHSE:600771
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600771 has been successfully added to your 
